
Blueprint Medicines Corporation BPMC
Blueprint Medicines Corporation ROE | BPMC
ROE Jährlich Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.46 | -388.17 | -108.32 | -66.35 | 21.35 | -74.88 | -56.48 | -23.74 | -34.02 | -36.65 | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 21.35 | -388.17 | -78.97 |
ROE Vierteljährlich Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.75 | -4.89 | -70.89 | -95.6 | -111.26 | -139.95 | -160.74 | -116.11 | -85.45 | -54.18 | -63.58 | -50.94 | -36.71 | -24.68 | 18.44 | 19.44 | 20.06 | 27.18 | 12.89 | -50.53 | -63.6 | -74.88 | -79.76 | -76.81 | -61.8 | -56.48 | -45.16 | -33.85 | -32.75 | -23.74 | -25.86 | -27.72 | -31.23 | -34.02 | -34.86 | -35.74 | -35.89 | -36.65 | -7.61 | 14.4 | 33.86 | 50.75 | 13.23 | 10.44 | 8.85 | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 50.75 | -160.74 | -36.87 |
ROE anderer Aktien in der Pharmaeinzelhändler
| Name | ROE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Myovant Sciences Ltd.
MYOV
|
43.5 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-197.53 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-84.78 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
1.94 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
6.42 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-143.06 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-74.53 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-103.99 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
607.06 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
1320.61 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
179.91 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
115.97 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-558.64 | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
763.35 | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-69.0 | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-92.01 | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-111.29 | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
-60.67 | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-95.79 | - | - | $ 127 M | ||
|
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
37.48 | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
-2.96 | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.58 | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
-24.78 | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
128.44 | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
-107.78 | - | - | $ 58.1 M | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
332.81 | - | -14.27 % | $ 1.7 M | ||
|
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | ||
|
BELLUS Health
BLU
|
-19.46 | - | - | $ 2.47 B | ||
|
Intra-Cellular Therapies
ITCI
|
-1.47 | - | - | $ 13.6 B | ||
|
Marinus Pharmaceuticals
MRNS
|
-843.45 | - | - | $ 29.6 M | ||
|
GeoVax Labs
GOVX
|
-251.41 | $ 1.83 | -4.45 % | $ 8.35 M | ||
|
Unity Biotechnology
UBX
|
-400.22 | - | -33.41 % | $ 3.37 M | ||
|
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | ||
|
Tyme Technologies
TYME
|
-29.5 | - | 8.07 % | $ 54 M | ||
|
Karuna Therapeutics
KRTX
|
-34.58 | - | - | $ 12.2 B | ||
|
Corner Growth Acquisition Corp.
COOL
|
108.33 | - | -0.89 % | $ 114 M | ||
|
Revance Therapeutics
RVNC
|
213.71 | - | - | $ 309 M | ||
|
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | ||
|
TRACON Pharmaceuticals
TCON
|
443.51 | - | -1.38 % | $ 46.8 M |